IthaMaps

Welcome to IthaMaps

IthaMaps is a global epidemiology database of heamoglobinopathies, illustrating published data on a dynamic global to regional map. Country-specific information on haemoglobinopathy-related policies, prevalence, incidence and overall disease burden is given, including relative allele frequencies of specific globin mutations in each country and/or region, dynamically linked to corresponding IthaGenes entries.

IthaMaps content was supported by partnership with the HVP Global Globin 2020 Challenge

Search

Search Country:		OR	Search for:		Show organisations

Healthcare information:
Major haemoglobinopathies:

Mutation search

Select locus:		Select mutation:

More Fewer search options

General information for Angola

Angola

Continent:	Africa
Capital:	Luanda
Population:	13068161
Area (in sq km):	1246700.0

Haemoglobinopathy-specific healthcare policy information for Angola

Healthcare policy		Comment/Info
Prevention programme:	No	There is no prevention programme in all country
SCD newborn screening:	Yes (Regional)	It is practiced at subnational level and is generally provided only in tertiary health facilities, and generally in private ones; ARISE is supporting a NBS in one Hopsital in Luanda
Prenatal screening:	No
Antenatal screening:	No
Haemoglobinopathies patient registry:	No	Some local tertiary public and some private health facilities have their own registry of Clinical data.
Rare disease patient registry:	No
Dedicated treatment centres:	Yes (Regional)	One local public instititute and some local secondary and tertiary ones
Blood transfusion availability:	Yes (National)	In hospitals where care is provided, there is always a shortage of voluntary donors and donors are generally are family members
Iron chelation availability:	No
MRI facilities:	No	Some institutions have access to CT and few ones have MRI facilities (private ones)
Patient associations:	Yes (Regional)	Almost non-existent, the few ones are NGOs, but there are 4 groups of patients
Genetic counselling:	No	Informally at the point of care or at the consultation

Prevalence and incidence of major haemoglobinopathies in Angola

Haemoglobinopathy		Comment/Info
Prevalence of sickle cell disease carriers:	22 % of the population	Based on the latest NBS data
Prevalence of Hb C carriers:	0.03 % of the population	Based on the latest NBS data
Incidence of sickle cell disease:	13300 affected births/year	approximately

Global Burden of Disease data for Angola

Migration data for Angola

Mutation frequencies in Angola

No mutation frequencies are currently available for Angola

Organisations in Angola

Organisations in Angola are currently not available

Microattributions

A/A	Contributor(s)	Date	Comments
1	Elion, Jacques	2017-10-17	Information on SCD newborn screening reviewed.
2	Brito, Miguel	2024-07-25	Information of healthcare policies reviewed.
3	Brito, Miguel	2024-09-26	Information on Haemaglobinopathy status parameters reviewed.

To provide new epidemiological information and/or report mistakes, please register/log in first or use the Contact Us form.

Important Note: The relative allele frequencies presented in IthaMaps are not calculated by ITHANET, but they are extracted from the corresponding publications. ITHANET is not responsible for any mistakes in the data. Please use this information with caution! We encourage scientists that have more detailed or updated epidemiological information to contact us.

Disclaimer: The information on this website is provided as an information resource only and must not to be used as a substitute for professional diagnosis and treatment. The ITHANET Portal and IthaMaps are not responsible or liable for any advice, course of treatment, diagnosis or any other information, services or products that an individual obtains through this website.

Note: The information you provide for the specific country will appear on the IthaMaps website and your contribution will be acknowledged.

Country:

Contributor's details

To be included in ITHANET Organisations & Experts

Name:		Organisation's name:
Surname:		Organisation's brief description:
Title:		Organisation's address:
Expertise/Research interests:		Organisation's City:
Address:		Organisation's Country:
City:		Organisation's website:
Country:		E-mail:
ORCID

Healthcare Policies

Health-policy	Select one Answer	Comment
Prevention programme
SCD newborn screening
Prenatal screening
Antenatal screening
Haemoglobinopathies patient registry
Rare disease patient registry
Dedicated treatment centres
Blood transfusion availability
Iron chelation availability
MRI facilities
Patient associations
Genetic counselling

Status of major Haemoglobinopathies

In Expected Incidence of β-thalassaemia and sickle cell disease please provide the number of expected affected births/year (without prevention).
In Incidence of β-thalassaemia and sickle cell disease please provide the number of affected births/year (after prevention).

Haemoglobinopathy	Provide value		Comment
Prevalence of β-thalassaemia carriers		% of the population
Prevalence of sickle cell disease carriers		% of the population
Prevalence of α-thalassaemia carriers		% of the population
Prevalence of Hb E carriers		% of the population
Prevalence of Hb C carriers		% of the population
Expected incidence of β-thalassaemia		expected affected births/year
Expected incidence of sickle cell disease		expected affected births/year
Expected incidence of α-thalassaemia		expected affected births/year
Incidence of β-thalassaemia		affected births/year
Incidence of sickle cell disease		affected births/year
Incidence of α-thalassaemia		affected births/year
Known β-thalassaemia patients		patients
Known sickle cell disease patients		patients

Mutation Frequencies

Please provide details about publications reporting mutation frequencies in the country of reference (either country-wide studies or region-specific studies).

Show on map:		Information to display:
Minimum sample size: